Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
29,821,897
-
Share change
-
+536,035
-
Total reported value
-
$446,643,807
-
Put/Call ratio
-
49%
-
Price per share
-
$14.98
-
Number of holders
-
123
-
Value change
-
+$8,492,661
-
Number of buys
-
69
-
Number of sells
-
43
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q4 2022
As of 31 Dec 2022,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,821,897 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, HHLR ADVISORS, LTD., Rubric Capital Management LP, STATE STREET CORP, PICTET ASSET MANAGEMENT SA, GOLDMAN SACHS GROUP INC, MILLENNIUM MANAGEMENT LLC, and ArrowMark Colorado Holdings LLC.
This page lists
123
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.